Arcus Biosciences develops investigational cancer medicines for patients and the doctors who treat them. RCUS reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). In the past 30 days there were 3 dark pool prints.
Prices, price targets and earnings estimates for RCUS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RCUS is in one of them and how their past RCUS trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Arcus Biosciences
Arcus Biosciences is a biopharmaceutical company based in Hayward, California. It develops investigational medicines, mainly for cancer, and tests them in clinical trials carried out with contract research organizations and trial sites. Its products are still investigational, and it works with partners such as AstraZeneca, Gilead and Taiho on some of its programs. Its intended users are cancer patients and the doctors who treat them.
